Drug used in heart surgery may increase the risk of death
The study tracked the long-term survival of nearly 3,900 heart patients who underwent coronary artery bypass surgery at 62 medical centers worldwide. The researchers tabulated survival at six weeks, six months, and then annually for five years.
The five-year death rate for patients given aprotinin was 20.8 percent, compared to 15.8 percent for those given another drug,
Aprotinin was approved for use in high-risk cardiac surgery patients by the U.S. Food and Drug Administration in 1993. After last year's report from Mangano's group, the FDA advised doctors to carefully monitor aprotinin patients for kidney, heart and brain damage -- an action taken after Bayer Pharmaceuticals, which markets the drug as Trasylol, disclosed study data showing that it increased the risk of death, kidney damage, congestive heart failure and stroke.
Read more of this story…